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Abstract
Epidemiological studies suggest an inverse association between soy intake and prostate cancer risk.
Genistein, the predominant phytoestrogen in soy food, has been proposed as a potential
chemopreventive agent due to its anti-estrogen and tyrosine kinase inhibitory effects. To determine
the most effective period for genistein chemoprevention, the Transgenic adenocarcinoma mouse
prostate (TRAMP) model was used. The treatments were 250 mg genistein/kg AIN-76A diet 1)
prepubertally only, 2) in adulthood only or 3) through out life. Controls received AIN-76A diet. By
28 weeks of age, 100% TRAMP mice fed control diet developed prostatic intraepithelial neoplasia
(PIN) or adenocarcinomas with 6%, 16%, 44% and 34% developing high grade PIN, well
differentiated, moderately differentiated and poorly differentiated prostatic adenocarcinomas,
respectively. Prepubertal only (1–35 days postpartum) and adult only genistein treatments (12 – 28
weeks) resulted in 6% and 29% decreases in poorly-differentiated cancerous lesions compared with
controls, respectively. The most significant effect was seen in the TRAMP mice exposed to
genistein throughout life (1–28 weeks) with a 50% decrease in poorly-differentiated cancerous
lesions. In a separate experiment in castrated TRAMP mice, dietary genistein suppressed the
development of advanced prostate cancer by 35% compared with controls. Of the tumors that
developed in castrated TRAMP mice, 100% were poorly-differentiated in contrast to the 37% of
noncastrated TRAMP mice that developed poorly-differentiated tumors. ICI 182,780 (ICI),
genistein and estrogen down-regulated androgen receptor (AR), estrogen receptor alpha (ER-α)
and progesterone receptor (PR) in the prostates of C57BL/6 mice, and act independently of ER.
Our data obtained in intact and castrated transgenic mice suggest that genistein may be a promising
chemopreventive agent against androgen-dependent and independent prostate cancers.
Background
Prostate cancer is the most frequently diagnosed cancer in
North American men and accounts for the second largest
number of male cancer deaths in the United States [1].
Clinically manifested prostate cancer is less prevalent
among Asian men where the intake of soy products is high
[2-4]. However, Asians who immigrate to the United
States and adopt a Western diet lose this protection [5-8].
High consumption of food containing soy results in high
plasma, urine, and prostatic fluid concentrations of phy-
toestrogens [9,10]. Genistein, the most abundant phy-
toestrogen component of soy, has been shown to inhibit
the growth of both androgen-dependent and independent
[11,12] prostate cancer cells. Prostate tumor incidence is
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significantly reduced in transgenic [13], spontaneous
[14], and chemically-induced [15] animal models after
ingestion of genistein in the diet at nutritionally relevant
concentrations. Mice fed genistein at concentrations of
250 mg/kg AIN-76A diet have serum concentrations at the
high physiological level (139 ± 70 nmol/L) [13], compa-
rable with those found in Asian men on a regular soy diet
(276 nmol/L) [9,10].
In the past, the study of prostate cancer chemoprevention
was hindered by the lack of appropriate animal models. In
recent years, genetically manipulated animals have pro-
vided new scope for chemoprevention studies and for
developing strategies to offset specific genetic susceptibil-
ities to cancer [16,17]. The major advantage of these trans-
genic models is that cancer arises spontaneously in their
natural tissue microenvironment and progresses through
multiple stages, as does human cancer. An autochthonous
transgenic animal model of prostate cancer, the TRAMP
model [18], was developed as a very important tool for
understanding the earlier events and the progression of
adenocarcinomas. TRAMP mice develop in situ and inva-
sive carcinoma of the prostate, mimicking the whole spec-
trum of human prostate cancer progression from prostatic
intra-epithelial neoplasia to large multinodular malignant
neoplasia [18-20], as well as androgen-independent dis-
ease [21]. Previously, we reported that genistein provided
in the diet starting at 5 weeks of age would suppress pros-
tate cancer development in the TRAMP model [13]. In the
present study, we investigated 1) timing of exposure to
genistein to determine if short term early exposure could
exert a permanent protective effect, if adult exposure only
would be effective in suppressing prostate tumor develop-
ment, or if life time genistein exposure was significantly
more efficacious, 2) the potential of genistein to suppress
androgen-independent prostate cancer, and 3) the
dependence of genistein action via the estrogen receptor
mechanism. Our results demonstrate that genistein in the
diet reduces the incidence of poorly differentiated pros-
tatic adenocarcinomas in both intact and castrated
TRAMP mice, that the most efficacious protocol is life
time exposure, and that genistein action in the prostate
occurs via the estrogen receptor.
Materials and methods
Chemicals
Genistein (98% pure, 1.5% methanol) was a gift from F.
Hoffmann-La Roche, Basel, Switzerland. Estradiol ben-
zoate (EB) and dimethyl sulfoxide (DMSO) were pur-
chased from SIGMA, St. Louis, MO. ICI 182,780 was
purchased from TOCRIS, Ellisville, MO.
Animal treatment
All animal studies were conducted in accordance with
established guidelines and protocols approved by the
UAB Animal Care Committee. Female heterozygous
TRAMPs in the background of C57BL/6 were obtained as
breeders from the NIH Mouse Models of Human Cancers
Consortium. In our studies, TRAMP mice were developed
on a pure C57BL/6 background, heterozygous for the pro-
basin-Tag transgene. To produce transgenic offspring,
ransgenic females were bred with non-transgenic males
because transgenic males develop prostate tumors. After
weaning at 3–4 weeks of age, males were separated from
females, and a tail biopsy was collected from each mouse.
Tail DNA, isolated by standard procedures, was used for
determination of transgene incorporation by PCR as
described previously [13,22]. Only the males that
screened positive for the Tag transgene were used. Male
and female breeders were fed standard pellet mouse feed
(Harlan Teklad, Madison, WI) until birth of offspring, and
then the dams and offspring were switched to AIN-76A
diet with or without genistein.
To determine the most effective period of genistein action
for chemoprevention 122 intact transgenic males were
divided into four treatment groups: 1) controls: transgenic
males fed powdered AIN-76A diet from birth until 28
weeks of age, 2) neonatal/prepubertal treatment only: 250
mg genistein/kg AIN-76A diet from birth until five weeks
of age, 3) adult exposure only: 250 mg genistein/kg AIN-
76A diet from 12 weeks of age until 28 weeks, and 4) life-
time exposure: 250 mg genistein/kg AIN-76A from birth
until 28 weeks. AIN-76A diet is a semi-purified diet con-
taining no detectable phytoestrogens. The dietary genis-
tein concentration is the same as the one used in our
previous chemoprevention and mechanism of action
studies [13,22].
To investigate the effect of genistein treatment on andro-
gen-independent prostate cancer development, TRAMP
males fed AIN-76A diet were anesthetized with Ketamine/
Xylazine and castrated at 12 weeks of age. After castration,
TRAMP males were divided into two groups. Controls
were continued on AIN-76A diet (n = 47), whereas the
others received 250 mg genistein/kg AIN-76A diet (n =
39) from 12 weeks onward. Animals in both groups were
monitored weekly for body weight, tumor progression by
abdominal palpation, and survival until 28 weeks of age.
Only castrated TRAMP males that developed prostate
tumors were used for data evaluation.
To investigate the role of sex steroid receptors and genis-
tein action in the prostate, C57BL/6 mice were used
because they were less expensive and labor intensive than
TRAMP males. Twelve week old mice were pretreated with
4 μg ICI/g BW 30 min prior to treatment with 500 μg gen-
istein/g BW, 50 ng EB/g BW or an equivalent volume of
DMSO (vehicle). The mice were killed six hours after the
last treatment and the dorsolateral prostates were dis-Journal of Carcinogenesis 2007, 6:3 http://www.carcinogenesis.com/content/6/1/3
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sected for analysis of AR, ER-α and PR. The ICI and genis-
tein concentrations were the same as used in mechanism
of action studies in female rats [23]. The EB concentration
was shown to be a minimally effective dose to regulate AR,
ER-α and PR in the mouse prostate. All injections were
subcutaneous. Preliminary experiments were carried out
to determine the length of time between genistein and EB
treatments to time of measuring the biomarkers. Each
group contained 7 samples with 6 dorsolateral prostates
each. In our studies, we focused our attention on the dor-
solateral prostate, because the dorsolateral lobes of the
murine prostate are embryologically homologous to the
human prostate [24] where approximately 68% of human
prostate cancers originate [25].
Necropsy and histopatholgy
Necropsy of tumor animals was conducted at 28 weeks of
age or when animals became moribund. All major organs
were inspected for frank toxicity or evidence of metastases.
Evaluations included quantitative and qualitative descrip-
tions of the prostate, lymph nodes, and any tissues show-
ing any visible abnormality. Any tissues containing visible
metastases or other abnormalities were also collected for
histological evaluation. The urogenital tract, including the
bladder, seminal vesicles, prostate and epididymes, were
removed, weighed, and prepared for pathological evalua-
tion as previously reported [13]. All tissues were fixed
overnight in 10% buffered formalin, and then transferred
to 70% ethanol. Fixed tissues were embedded in paraffin,
and 5 μm sections were mounted on Colorfrost/Plus
microscope slides (Fisher Scientific, Hampton, NH). Sec-
tions were stained with hematoxylin and eosin. Histolog-
ical sections of all tissues were evaluated and reviewed by
a board certified pathologist (Dr. I-E. Eltoum) using a
scale that has been established for the TRAMP model [26].
Noncancerous lesions were graded as normal tissue, low
PIN and high PIN, respectively. Well-, moderately- and
poorly-differentiated were used to describe cancerous
lesions.
Immunoblotting
To determine the changes in the expression of AR, ER-α,
and PR, prostate tissues were homogenized in RIPA lysis
buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA; Upstate Bio-
technology, Charlottesville, Virginia), plus protease
inhibitors: 1 μg/ml aprotinin (SIGMA), 1 μg leupeptin
(SIGMA), 1 mM PMSF (SIGMA), 1 mM Na3VO4
(SIGMA), and 1 mM NaF (SIGMA). Protein concentration
of each sample was determined using the Bradford micro-
titer plate assay (BioRad, Hercules, CA). The same quan-
tity of protein from each sample was separated by SDS-
PAGE and transferred to a nitrocellulose membrane (Bio-
Rad, Hercules, CA). The membranes were blocked and
immunoblotted with appropriate antibodies including a
polyclonal antibody to the amino acid portion of the
human AR (N-20) (Santa Cruz, CA); anti-ER-α polyclonal
IgG (MC-20) (Santa Cruz); anti-PR (C-19) (Santa Cruz);
Molecular weight ladders and reference proteins from the
respective companies were used as positive controls. After
incubation with HRP-conjugated anti-mouse or anti-rab-
bit secondary antibody (Pierce, Rockford, IL), protein
blots were detected with SuperSignal West Dura Extended
Duration Substrate as described by the manufacturer
(Pierce, Rockford, IL) and exposed to X-ray radiography
film. Quantitative analysis of protein expression was
accomplished by scanning autoradiograms and densitom-
etry.
Data analysis
Statistical analysis of histological specimens used Fisher's
exact test to determine significance (P < 0.05). Analyses
were conducted using Microsoft Office Excel 2003 (Micro-
soft Corp., Seattle, WA). For the biochemical data, experi-
ments were analyzed using one way analysis of variance
(ANOVA), with subsequent multiple comparisons. The p-
values associated with the individual comparisons were
completed using separate t-tests.
Results
Prostate cancer chemoprevention in intact TRAMPs
A total of 122 TRAMP males were stratified among four
different groups according to genistein treatment. Dietary
exposure to genistein in the diet at 250 mg/kg diet did not
alter body weights at 3, 5 and 28 weeks in all groups (data
not shown). Likewise, there were no observed differences
in food or water consumption between the control and
genistein treated groups. At 28 weeks of age, none of the
TRAMP mice on control diet had normal prostates, or low
grade PIN (Table 1). Six percent had high grade PIN and
16% had well-differentiated cancerous lesions. In
TRAMPs fed control diet, 44% and 34% displayed moder-
ately- and poorly- differentiated carcinomas, respectively.
Genistein in the diet from birth until 5 weeks of age only
(neonatal/prepubertal exposure), did not alter the devel-
opment of prostate cancer pathology. However, adult
only exposure (weeks 12–28) resulted in a 29% decrease
in poorly-differentiated cancerous lesions (34% to 24%).
Consistent with this was a 34% increase in moderately dif-
ferentiated tumors (44% to 59%). The greatest effect was
seen in TRAMP exposed to genistein throughout life (1–
28 weeks) with a 50% decrease in poorly-differentiated
cancerous lesions (34% to 17%). This was accompanied
by a 36% increase in moderately differentiated tumors
(44% to 60%). Although the percentage of control ani-
mals with a score of poorly differentiated tumors was
twice that of those fed genistein in the diet for 196 days,
there was no statistical difference (Fisher's exact test: p =
0.15). Nevertheless, these data strongly suggest that life-
time, and perhaps adult only, genistein exposure can sup-Journal of Carcinogenesis 2007, 6:3 http://www.carcinogenesis.com/content/6/1/3
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press spontaneously developing prostate cancer in the
TRAMP model.
Prostate cancer chemoprevention in androgen-
independent TRAMP model
In 47 castrated TRAMP mice fed control diet only, 66%
were evaluated as having normal prostates while 6% and
3% were characterized as low and high PIN, respectively
(Table 2). While no castrated TRAMPs had well differenti-
ated and moderately differentiated adenocarcinomas,
23% displayed poorly differentiated prostate adenocarci-
nomas. Of those with poorly differentiated adencarcino-
mas, 27% had lymph node metastases. In animals
provided genistein in the diet from time of castration at 12
weeks until necropsy at 28 weeks, the percent of poorly
differentiated prostate tumors was decreased by 35%
(from 23% to 15%). Likewise, lymph node metastasis (all
poorly differentiated) was decreased by 50% (6% to 3%)
in genistein-treated mice.
Genistein, estrogen and ICI regulation of steroid receptors 
in prostates of C57BL/6 mice
Since genistein is a phytoestrogen we sought to determine
the role of ER in the prostate by blocking ER action with
the pure ER antagonist, ICI. We included the use of estra-
diol benzoate as a positive estrogen treatment. In addition
to measuring ER, we measured expression of PR, a protein
dependent on ER action [23], and AR since it plays such a
prominent role in the prostate. As expected, ICI signifi-
cantly down-regulated ER-α in the prostate (Figure 1).
Likewise, estrogen and genistein had the same effect,
albeit genistein was not as effective as estrogen. Further-
more, estrogen and genistein administered with ICI
resulted in an additive decrease of ER-α expression. In ref-
erence to PR, ICI, estrogen and genistein down-regulated
it (Figure 2). However, estrogen administered after ICI
resulted in significantly higher PR expression than when
estrogen and ICI were administered alone. Genistein
administered after ICI resulted in significantly higher PR
expression than when ICI was administered alone, but not
significantly different from genistein alone. The actions of
ICI, estrogen, and genistein administered alone, were able
to decrease AR expression in the prostate (Figure 3). In ref-
erence to the sequential administration of ICI followed by
estrogen, AR protein expression was significantly higher
compared to ICI, but not to estrogen treatment. On the
other hand, genistein injection after ICI resulted in
increased AR compared to single ICI or genistein treat-
ments.
Discussion
As people live longer, this aging population results in a
higher incidence of prostate cancer. Hence, there is need
for novel preventive approaches for the management of
this disease. Chemoprevention by the use of dietary
agents offers a viable option to block the neoplastic incep-
tion or delay disease progression. Because prostate cancer
is typically diagnosed in men aged 50 years and older,
even a slight delay in the onset and subsequent progres-
sion of the disease through the use of dietary agents could
have important health benefits. Ideally, the efficacy of
such chemopreventive agents should be verified in animal
models that emulate human disease before recommend-
ing their use for humans. In this study, we have used both
intact and castrated TRAMP models to evaluate the effect
of dietary genistein on prostate cancer development. The
advantage of the TRAMP model is that, because of its
genetic makeup, initiation of prostate cancer occurs spon-
taneously. Longitudinal studies in TRAMP mice have
shown that over the period of 8–12 weeks of age, this
mouse displays progressive stages of prostate cancer
found in humans [18-21]. As expected, TRAMP mice pro-
Table 1: Effect of genistein on primary pros tate neoplasia in intact TRAMP mice
Genistein (wk) n PIN 1 (%) PIN 2 (%) PIN 3 (%) WDC (%) MDC (%) PDC (%)
None 32 0 0 2 (6) 5 (16) 14 (44) 11 (34)
1–5 31 0 0 2 (6) 7 (23) 12 (39) 10 (32)
12–28 29 0 2 (7) 2 (7) 1 (3) 17 (59) 7 (24)
1–28 30 1 (3) 0 3 (10) 3 (10) 18 (60) 5 (17)
TRAMP mice were sacrificed at 28 weeks of age, and the percentage of mice with normal prostate tissue (PIN 1), low-PIN (PIN 2), high-PIN (PIN 
3), well-differentiated carcinoma (WDC), moderately differentiated carcinoma (MDC), and poorly differentiated carcinoma (PDC) was determined.
Table 2: Effect of genistein on primary prostate neoplasia and lymphatic metastases in castrated TRAMP.
Description n PIN 1 (%) PIN 2 (%) PIN 3 (%) WDC (%) MDC (%) PDC (%) LNM (%)
Controls 47 31 (66) 3 (6) 2 (4) 0 0 11 (23) 3 (6)
Genistein 39 27 (69) 4 (10) 2 (5) 0 0 6 (15) 1 (3)
TRAMP were castrated at 12 weeks and sacrificed at 28 weeks of age. Percentage of mice with normal prostate tissue (PIN 1), low-PIN (PIN 2), 
high-PIN (PIN 3), well-differentiated carcinoma (WDC), moderately differentiated carcinoma (MDC), and poorly differentiated carcinoma (PDC) 
was determined.Journal of Carcinogenesis 2007, 6:3 http://www.carcinogenesis.com/content/6/1/3
Page 5 of 10
(page number not for citation purposes)
duced in our lab developed progressive forms of prostatic
disease that resemble human prostate cancer. Careful
pathological evaluation revealed that by 28 weeks of age,
none of the 32 TRAMP mice on control diet had normal
prostates or low PIN. Instead, 94% displayed prostatic
adenocarcinomas and 6% had high grade PIN.
For our chemoprevention studies, we focused on the
potential of timing of genistein exposure to protect
against prostate cancer, a concept that we have shown to
be important in genistein suppressing chemically-induced
mammary cancer in rats. In the latter, neonatal and prepu-
bertal genistein exposure was necessary to program
against mammary cancer [27,28]. However, our prostate
cancer studies demonstrated that genistein exposure dur-
ing the neonatal and prepubertal periods only did not
suppress prostate cancer development in TRAMPs. On the
other hand, genistein in the diet to adult TRAMP mice
resulted in a 29% decrease in poorly-differentiated aden-
ocarcinomas. More effective was life-time genistein treat-
ment. It resulted in a 50% decrease in poorly-
differentiated prostate tumors. With both of these genis-
tein treatment groups, the chemoprevention was associ-
ated with suppressing the rate of cancer development as
evidenced by increased percentage of prostate cancer
manifested as moderately differentiated tumors, (44% to
60%). This chemoprevention data is supportive of our
earlier studies with genistein action in TRAMPs where
genistein in the diet at increasing concentrations starting
at 5 weeks suppressed spontaneously developing prostate
tumors in a dose-dependent manner [13].
In addition to prostatectomy, radiation and/or chemo-
therapy, androgen deprivation (castration) has been used
as a means of prostate cancer therapy. In most patients the
latter leads to reduction in the growth of the primary
tumor and its metastases. Unfortunately, the effect lasts
only for a year or two. Cancer cells then become androgen
independent; they grow (relapse) and eventually kill the
patient. Hence, an agent that could prevent or control
androgen-independent prostate cancer would have imme-
diate clinical importance. Previously, it was shown that
castration of TRAMPs resulted in androgen independent
prostate cancer development [21]. Hence, another charac-
Estrogen receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein (G) or  estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed 16 h  later Figure 1
Estrogen receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein (G) or 
estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed 16 h 
later. a P < 0.001 compared to controls; b P < 0.001 compared to ICI 182,780 treatment; c P < 0.001 compared to estrogen or 
genistein treatments.
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teristic of the TRAMP model is its similarity to human dis-
ease in the progression to androgen-independent prostate
cancer. For our studies, we castrated the mice at 12 weeks,
a protocol that is similar to that described by Gingrich et
al. [21]. However, we observed only 23% of the TRAMP
mice on control diet developing cancerous lesions, with
all of them being poorly differentiated prostate tumors.
This is to be contrasted to the report of Gingrich et al. that
80% of TRAMP mice developed prostate tumors as early
as 12 weeks post castration [21]. Our only explanation for
this difference is that they used FVB mice as male back-
ground breeders and we used C57BL/6 male mice as back-
ground breeders. Apparently, the C57BL/6 background
TRAMPs are more resistant to androgen-independent
prostate cancer development, thus providing another use-
ful model of prostate cancer study.
Importantly for our study, genistein in the diet suppressed
prostate cancer development in these castrated TRAMP
mice by 35% and lymph node metastases by 50%. The
ability of genistein to reduce poorly differentiated cancer
incidence in this model suggests that it may be able to
control androgen-independent prostate cancer in man.
This is an important manifestation because the latter is a
very aggressive and lethal form of cancer. Furthermore, it
is most useful and convenient to have the same nutri-
tional agent suppress both androgen-dependent and inde-
pendent prostate cancers.
Androgen and estrogen play a role in the normal develop-
ment of the male reproductive tract and are believed to
contribute to prostate cancer development [29,30]. Since
genistein has been shown to bind to estrogen receptors
and to exert estrogen like activity in the female reproduc-
tive tract, it has been categorized as a phytoestrogen. How-
ever, not all estrogens are exactly the same. Estrogenically-
active chemicals are of varying potency and, more impor-
tantly, have additional biological actions that can lead to
different mechanisms. While genistein action has been
extensively investigated in the female, less is known of its
Progesterone receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein  (G) or estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed  16 h later Figure 2
Progesterone receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein 
(G) or estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed 
16 h later. a P < 0.001 compared to control; b P < 0.001 compared to ICI; c P < 0.05 compared to estrogen treatment; d P < 0.05 
compared to ICI treatment.
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actions in the male reproductive tract. For this reason, we
investigated the potential of genistein to act via the ER
mechanism using the potent and pure estrogen antago-
nist, ICI. Mechanistically, the down-regulation of ER-α
protein by ICI is thought to be inhibition of and a change
in ER conformation which leads to a rapid loss of ER via
proteolysis [31,32]. This down regulation of ER is in
agreement with our results showing approximately 80%
decrease in the ER-α level after ICI treatment. Also, our
data demonstrates that ICI was able to down-regulate PR
and AR, actions consistent with ICI being a steroid recep-
tor antagonist, even in the prostate.
Studies using cells transfected with ER and PR reporter
genes have demonstrated extensive inhibitory cross-reac-
tivity between ER and PR. Both progestins (R5020) and
anti-progestins (RU-486) have been shown to act as
potent ligand-dependent repressors of ER activity when
bound to either isoform of PR [33]. A recent study has
pointed to 'reverse' cross-reactivity between these recep-
tors, i.e. blocking of progestin-induced transcription by
ICI [34]. Hence, ICI has weak anti-progestational activity
[35]. This antiprogestational, in addition to its antiestro-
genic, activity of ICI may be important in relation to its
anti-cancer activity in vivo. In the prostate, AR has been
shown to be down-regulated by estrogen during develop-
ment [29,30]. In our study, AR levels were significantly
decreased in the prostate of TRAMPs treated with ICI, sug-
gesting that AR is dependent on ER-α action to be main-
tained or that ICI has anti-androgen activity.
Interestingly, estrogen and genistein given alone also
down-regulated these three sex steroid receptors. Others
have shown that ICI is similar to estradiol in its ability to
decrease its receptor expression [36,37]. Furthermore,
estrogen and genistein given after ICI resulted in addi-
tional decrease in ER-α protein in the prostate, suggesting
that all three chemicals can act via ER. Estrogen and genis-
tein may be decreasing the ER-α via feedback/degradation
mechanisms rather than directly inhibiting the receptor.
Androgen receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein (G)  or estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed 16 h  later Figure 3
Androgen receptor expression in dorsolateral prostates of adult mice treated with one injection of vehicle (C), genistein (G) 
or estradiol benzoate (E) (with or without pretreatment with ICI 182,780 (I) thirty min prior to injection), and sacrificed 16 h 
later. a P < 0.001 compared to controls; b P < 0.001 compared to ICI; and c P < 0.05 compared to genistein treatment.
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In contrast to ER, PR and AR respond differently to estro-
gen and genistein given after ICI administration. While
ICI down regulated PR and AR, estrogen and genistein
given 30 min after ICI resulted in increased PR and AR,
partially reversing the ICI effect. This suggests that the
effect of ICI on PR and AR is not permanent and that gen-
istein and estrogen do not act exactly like ICI. It has previ-
ously been demonstrated that estrogen down regulates ER
by feedback/degradation mechanism, but ICI irreversibly
and directly inhibits and degrades the ER. It appears that
genistein acts similar to estrogen in the prostate. What is
not known is whether genistein and estrogen have other
mechanisms that make them distinct from each other.
The AR, a member of the steroid receptor family that is
activated by testicular androgens, is the major regulatory
transcription factor in normal prostate growth and devel-
opment and in the growth of androgen-dependent pros-
tate cancer. The AR may also contribute to prostate cancer
growth during its recurrence in the androgen-deprived
patient. A role for AR-mediated gene activation in recur-
rent prostate cancer is supported by its expression [38,39]
together with the expression of androgen-regulated genes
[40]. Possible mechanisms for AR reactivation in recurrent
prostate cancer include altered growth factor-induced
phosphorylation [41-45] and AR mutations [46] that
broaden ligand specificity [47]. ER-α, expressed mainly in
the stromal compartment of the prostate, may contribute
to the pathogenesis of prostate cancer. In a study of the
genotypic and allelic frequencies of the six different poly-
morphic loci of ER-α in a Japanese population, polymor-
phism in codon 10 of ER-α was found to be a possible risk
factor for prostate cancer [48]. Down-regulation of AR and
ER-α expression in prostate could be beneficial for chem-
opreventive activity of genistein. We have previously
reported that genistein down-regulated growth factor sig-
naling proteins in the TRAMP model [22]. More specifi-
cally, genistein in the diet down-regulated EGF-receptor,
IGF-1 receptor and extracellular signaling regulating
kinases (ERKs 1 and 2).
The interaction of sex steroid and growth factor signaling
pathways is thought to be critical in the process of devel-
opment and differentiation of hormone-responsive tis-
sues, and for cancer development in the prostate [49].
However, it is unclear whether steroid hormones are
mediating the effects of growth factors, or vice versa. Sex
steroid-induced epithelial cell proliferation and differenti-
ation have been associated with the coordinated induc-
tion of several peptide growth factors and their receptors,
including some that are tyrosine kinase dependent. In par-
ticular, the EGF- and IGF-signaling pathways are involved
in the regulation of cell growth and differentiation. These
two protein tyrosine kinase receptors undergo phosphor-
ylation and then utilize their intrinsic kinase activity to
phosphorylate downstream mitogen-activated protein
kinases, eventually leading to regulation of transcription
[reviewed in 50 and 51]. ERK-1 and ERK-2 are particularly
important to signal transduction pathways; including
nuclear transcription factor regulation, ultimately control-
ling gene expression. It has been hypothesized that the
duration of ERK activity may play a role in control of cel-
lular proliferation and differentiation [52].
It remains to be determined if the action of genistein is
directly on these proteins or as a consequence of the AR
and ER signaling mechanisms. Estrogen action is strongly
related to the EGF and IGF systems with evidence for
cross-talk between the systems at several levels [50,51].
The IGF-1R is directly activated by liganded ER, and IGF
signaling transcriptionally activates the ER. These growth
factor signaling proteins have synergistic effects on cell
cycle signaling cascades and proliferation [53]. Genistein
has been reported to regulate protein tyrosine kinases [54]
of which the EGF- and IGF-1 receptors are examples. Our
data points to the actions of genistein in the prostate and
the complex regulation of the sex steroid and tyrosine
kinase regulated growth factor signaling pathways. Given
the similarity of action of genistein and estrogen in the
current study, we hypothesize that binding to ER is the
primary event of genistein in the prostatic response with
biological manifestations for chemoprevention, but with-
out the potent toxic effects of estrogen. In addition to reg-
ulating sex steroid- and growth factor-signaling, genistein
possess potent anti-oxidant properties [55].
In conclusion, with the androgen dependent model
(intact TRAMP), incidences of poorly differentiated pros-
tate tumors were decreased 50% with genistein treatment.
Also, we conclude that genistein is effective in suppressing
poorly differentiated prostate cancer and metastasis in
androgen-independent TRAMP. The mechanisms of gen-
istein chemopreventive activity appears to be through
steroid receptor and growth factor signaling pathways.
Abbreviations
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